Literature DB >> 7014784

Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation.

F X Heinz, C Kunz, H Fauma.   

Abstract

By the use of continuous-flow zonal ultracentrifugation, a highly purified, inactivated tick-borne encephalitis (TBE) virus vaccine was prepared tht contained almost exclusively TBE virus particles. The purity of this preparation was 90- to 100-fold higher than that of a previously used partially purified vaccine. A mean protein content of 3-5 microgram/ml in the final vaccine represents 20 mouse protective doses50 in a mouse challenge potency test. This high degree of purity resulted in a strong reduction of side reactions observed with the less purified vaccine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7014784     DOI: 10.1002/jmv.1890060304

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

3.  Tick-borne Encephalitis Vaccines.

Authors:  Axel T Lehrer; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011

4.  Severe tick-borne encephalitis following passive immunization.

Authors:  K Waldvogel; W Bossart; T Huisman; E Boltshauser; D Nadal
Journal:  Eur J Pediatr       Date:  1996-09       Impact factor: 3.183

Review 5.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model.

Authors:  T R Kreil; M M Eibl
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 7.  Downstream processing of cell culture-derived virus particles.

Authors:  Michael W Wolf; Udo Reichl
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.